Drugs / TEMSAVIR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02805556 | Mar → May 2016 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2014-03-05 | Bristol-Myers Squibb | Results Bristol-Myers Squibb Presents Promising Phase IIb Data for Novel, Investigational Attachment Inhibitor for HIV-1 Infected Treatment-Experienced Patients bms.com ↗
Bristol-Myers Squibb Company (NYSE:BMY) today presented 24-week Phase IIb data that demonstrated similar response rates (HIV-1 RNA < 50 c/mL) for its investigational compound, BMS-663068, when compared to a boosted protease inhibitor, Reyataz ® (atazanavir sulfate) with ritonavir. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2014-03-05 | Bristol-Myers Squibb | Bristol-Myers Squibb Presents Promising Phase IIb Data for Novel, Investigational Attachment Inhibitor for HIV-1 Infected Treatment-Experienced Patients bms.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TEMSAVIR | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301620 ↗ |
| Known as | BMS-626529 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02805556 ↗ |
| Modality | Small molecule | — CHEMBL3301620 ↗ |
| Route | Intravenous | “Single intravenous dose of \[13C\]BMS 626529” NCT02805556 ↗ |